ArticleMolecular cancer therapeutics2014
MicroRNA-26b represses colon cancer cell proliferation by inhibiting lymphoid enhancer factor 1 expression.
Article in Molecular cancer therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- A Novel Circulating microRNA Signature Panel as a Prognostic Biomarker for in Patients with Colorectal Cancer.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Unbiased profiling of translational landscape reveals TNFR2 as a translation-dependent vulnerability in colorectal cancer.Journal of experimental & clinical cancer research : CR · 2026Article
- MicroRNAs in colorectal cancer: A comparative analysis of circulating and tissue microRNA levels.World journal of gastrointestinal oncology · 2025Article
- Analysis of immune infiltration in basal cell carcinoma based on transcriptome sequencing and experimental validation of diagnostic biomarkers.Discover oncology · 2025Article
- Identification of novel gut microbiota-related biomarkers in cerebral hemorrhagic stroke.Frontiers in medicine · 2025Article
- Molecular detection of exosomal miRNAs of blood serum for prognosis of colorectal cancer.Scientific reports · 2024Article
- Establishment of SLC7A11-knockout mouse and its preliminary investigation in melanoma.In vitro cellular & developmental biology. Animal · 2023Article
- Exploring microRNAs in craniofacial regenerative medicine.Biochemical Society transactions · 2023Review
- An integrated approach to understand fluid shear stress-driven and reactive oxygen species-mediated metastasis of colon adenocarcinoma through mRNA-miRNA-lncRNA-circRNA networks.Molecular genetics and genomics : MGG · 2022Article
- GeromiRs Are Downregulated in the Tumor Microenvironment during Colon Cancer Colonization of the Liver in a Murine Metastasis Model.International journal of molecular sciences · 2021Article
- A Cohort Study of Antihyperglycemic Medication Exposure and Gastric Cancer Risk.Journal of clinical medicine · 2020Article
- miRNA Regulation of Glutathione Homeostasis in Cancer Initiation, Progression and Therapy Resistance.MicroRNA (Shariqah, United Arab Emirates) · 2020Review
- Ectodermal Organ Development Is Regulated by aFrontiers in physiology · 2020Article
- Long noncoding RNA LEF1-AS1 silencing suppresses the initiation and development of prostate cancer by acting as a molecular sponge of miR-330-5p via LEF1 repression.Journal of cellular physiology · 2019Article
- lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer.Journal of hematology & oncology · 2019Article
- MicroRNA 26b promotes colorectal cancer metastasis by downregulating phosphatase and tensin homolog and wingless-type MMTV integration site family member 5A.Cancer science · 2018Article
- MiR-26b regulates 5-FU-resistance in human colorectal cancer via down-regulation of Pgp.American journal of cancer research · 2018Article
- Article
- Regulation of proliferation, angiogenesis and apoptosis in hepatocellular carcinoma by miR-26b-5p.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Expression of microRNA‑26b and identification of its target gene EphA2 in pituitary tissues in Yanbian cattle.Molecular medicine reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
microRNAs (miR) can act as oncogenes and tumor suppressors and several miRs are associated with cancer development and progression through the modulation of multiple cellular processes. miR26b is downregulated in several cancers and tumors and miR26b directly targets the lymphoid enhancer factor 1 (Lef1)3'UTR and inhibits endogenous Lef1 expression. We report that miR26b expression is associated with human colon cancer through the regulation of LEF1 expression in colon cancer cells. Analyses of multiple colon cancer cell lines revealed an inverse correlation between miR26b and LEF1 expression. Normal human colon cells express low levels of LEF1 and high levels of miR26b; however, human colon cancer cells have decreased miR26b expression and increased LEF1 expression. We demonstrate that miR26b expression is a potent inhibitor of colon cancer cell proliferation and significantly decreases LEF1 expression. The LEF1-regulated genes cyclin D1 and c-Myc were indirectly repressed by miR26b and this was consistent with decreased proliferation. miR26b overexpression in SW480 colon cancer cells also inhibited tumor growth in nude mice and this was due to decreased tumor growth and not apoptosis. Analyses of human colon cancer databases also demonstrated a link between miR26b and LEF1 expression. c-Myc expression is associated with multiple cancers and we propose that miR26b may act as a potential therapeutic agent in reducing cancer cell proliferation through repressing LEF1 activation of c-Myc and cyclin D1 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.